Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

Financial Statements (IFRS)

 

Balance Sheets

(in CHF thousands)

       

As of

December 31,

    Note   2018   2017
ASSETS            
Non-current assets            
Property, plant and equipment   4   3,324   2,353
Long-term financial assets   5   304   126
Total non-current assets       3,628   2,479
Current assets            
Prepaid expenses   6   2,364   1,440
Accrued income   6   3,667   2,799
Finance receivable   10   199  
Other current receivables   7   236   918
Short-term financial assets   5   30,000  
Cash and cash equivalents   5   156,462   124,377
Total current assets       192,928   129,534
Total assets       196,556   132,013
             
SHAREHOLDERS’ EQUITY AND LIABILITIES            
Shareholders’ equity            
Share capital   8   1,351   1,147
Share premium   8   298,149   188,299
Accumulated losses       (121,877)   (72,607)
Total shareholders’ equity       177,623   116,839
             
Non-current liabilities            
Long-term debt obligation   10   186   494
Net employee defined benefit liabilities   15    5,665   4,926
Total non-current liabilities        5,851   5,420
             
Current liabilities            
Trade and other payables   9   1,979   1,092
Accrued expenses   9   10,420   8,307
Deferred income   9   351   355
Short-term debt obligation   10   332  
Total current liabilities        13,082   9,754
Total liabilities        18,933   15,174
Total shareholders’ equity and liabilities        196,556   132,013

  

The accompanying notes are an integral part of these financial statements. 

 

 F-4


© AC Immune 2015